Establishment of Human Cellular Disease Models for Wilson Disease
NCT03867526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2021-04-09
Summary
Establishment of human cellular disease models for Wilson disease for an individualized therapy develop-ment having the capacity to address both hepatic and neurologic forms of the disease
Conditions
- Wilson Disease
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Arndt Rolfs, Prof. Dr. · CENTOGENE GmbH Rostock
Eligibility
- Min Age
- 6 Months
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-19
- Primary Completion
- 2019-12-01
- Completion
- 2019-12-01
Countries
- Pakistan
Study Locations
More Related Trials
-
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders
NCT03812055 ·Status: UNKNOWN
-
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
NCT06967831 ·Status: RECRUITING
-
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
NCT07266324 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Effect of Enzyme Replacement Therapy in Mucopolysaccharidosis
NCT05006222 ·Status: COMPLETED ·Phase: NA
-
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
NCT00076102 ·Status: COMPLETED ·Phase: PHASE2
-
Fast-track Surgery in the Treatment of Hirschsprung's Disease
NCT02350088 ·Status: UNKNOWN ·Phase: NA
-
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
NCT01275586 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
NCT04167345 ·Status: TERMINATED ·Phase: PHASE2
-
Stem Cell Gene Therapy for Cystinosis
NCT03897361 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
NCT07173933 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
NCT05705674 ·Status: RECRUITING
-
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT00634270 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
NCT07348601 ·Status: RECRUITING ·Phase: PHASE2
-
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
NCT03533673 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
NCT00157118 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001 ·Status: RECRUITING ·Phase: PHASE2
-
Precision Medicine for Neurocutaneous Syndromes in Western China
NCT07327164 ·Status: COMPLETED
-
Biomarker for Sly Disease (MPS VII) (BioSly)
NCT02298699 ·Status: WITHDRAWN
-
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II
NCT05665166 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Orphan Drugs for Inherited Metabolic Diseases
NCT05818566 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
NCT00344331 ·Status: RECRUITING
-
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
NCT00515398 ·Status: COMPLETED
-
Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A
NCT00957749 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
NCT02124083 ·Status: COMPLETED ·Phase: PHASE1/PHASE2